Monjuvi by MorphoSys AG - targeted lymphoma therapy gains ground

Monjuvi is poured into a clear infusion bag, the liquid catching the harsh white light of the oncology ward as nurses double-check the patient label. This antibody therapy from MorphoSys AG has become a quiet but important presence in treatment rooms for aggressive blood cancer.

Antibody for tough lymphoma cases

Monjuvi is a CD19-directed monoclonal antibody, developed by MorphoSys together with US partner Incyte for adult patients with relapsed or refractory diffuse large B-cell lymphoma, or DLBCL, who are not eligible for stem cell transplant. This indication targets a group with limited options after standard chemoimmunotherapy.

In clinical use, Monjuvi is typically given in combination with lenalidomide and followed by monotherapy, under the brand name Monjuvi in the US and Europe and Minjuvi in some other markets. The regimen is administered intravenously, with dosing adjusted by body weight and premedication to reduce infusion-related reactions.

From lab concept to approvals

Chief Executive Officer Jean-Paul Kress has repeatedly highlighted Monjuvi as a cornerstone example of MorphoSys’s transition from a pure antibody discovery player to a commercial-stage biopharmaceutical company. The antibody originated from MorphoSys’s HuCAL technology platform and advanced through multiple development stages with Incyte handling much of the US commercial effort.

Regulatory momentum started in 2020 when the US Food and Drug Administration granted Monjuvi accelerated approval for relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low-grade lymphoma, in adults who are not candidates for autologous stem cell transplant. The European Commission followed with a conditional marketing authorization under the brand name Minjuvi, broadly mirroring the US indication but with some regional nuances.

Dosing, safety and hospital routine

The standard regimen combines Monjuvi with lenalidomide for up to twelve 28-day cycles, after which Monjuvi monotherapy can continue until disease progression or unacceptable toxicity, according to the US prescribing information. Infusions are typically given on days 1, 8 and 15 during the first cycles, then less frequently as the schedule advances.

On safety, the label warns of serious adverse reactions such as infusion-related reactions, infections, cytopenias and potential fetal harm, requiring close monitoring and supportive care. Nurses often remark on the need for careful premedication and observation during early infusions, particularly in patients with bulky disease or poor general status, to catch any acute reactions promptly.

Evidence from the L-MIND study

The backbone of Monjuvi’s clinical profile is the L-MIND trial, an open-label, single-arm Phase 2 study evaluating tafasitamab (the non-proprietary name for Monjuvi/Minjuvi) plus lenalidomide in adult patients with relapsed or refractory DLBCL who are ineligible for autologous stem cell transplant. This trial enrolled patients after one to three prior treatment lines, many of whom had high-risk features.

Published L-MIND data reported an overall response rate around 60%, with complete responses in roughly 40% of patients and a median duration of response exceeding two years among responders, according to peer-reviewed hematology journals. These numbers compare favorably with historical outcomes on salvage chemotherapy alone in this population, which tended to deliver much lower durable response rates.

Position among other lymphoma options

Hematologists today navigate a crowded landscape of options for relapsed or refractory DLBCL, including CAR-T cell therapies, antibody-drug conjugates and small molecule targeted agents. Monjuvi carves out a place particularly for patients not considered suitable for aggressive approaches like autologous transplant or CAR-T, often due to age, comorbidities or logistical barriers.

In discussions at conferences, clinicians mention that Monjuvi’s fixed-duration combination phase followed by single-agent maintenance can provide a manageable schedule for patients and infusion centers, compared with the intensive preparation and monitoring required for cell therapies. However, they also underline that cross-trial comparisons are tricky, and each case needs individual risk–benefit assessment.

Market footprint and pricing aspects

Monjuvi is commercialized by MorphoSys and Incyte, with a profit share agreement in the United States and differing regional arrangements elsewhere. Incyte handles most US commercialization, while MorphoSys focuses on Europe and some other territories through its own organization and distribution partners. Revenue from Monjuvi is reported in MorphoSys’s oncology segment.

Official list prices for monoclonal antibody oncology therapies are high, though net prices depend on discounts, reimbursement negotiations and patient assistance programs. For Monjuvi, US wholesale acquisition cost per vial has been reported in industry sources as being in line with other branded CD20 and CD19-directed biologics, but precise current figures vary by setting. In Europe, specific country list prices are set at national level, and access is often governed by health technology assessments and negotiated rebates.

Who receives Monjuvi today

In everyday practice, Monjuvi typically finds its way to patients who have already received rituximab-based chemoimmunotherapy and are facing disease that has either not responded adequately or has returned. These patients may be older or frail, making intensive salvage regimens or transplant less realistic options.

Clinical teams in hematology wards describe that once Monjuvi is selected, pharmacy preparation and nursing protocols become routine: vials are checked, the solution is diluted into saline, and infusion pumps are programmed for the prescribed rate. Patients often sit in reclining chairs or beds, with the soft beep of monitors accompanying each cycle.

Future development and combinations

Beyond its current approved indication, tafasitamab is being investigated in several combination regimens and lines of therapy, according to ongoing clinical trial registries. Trials explore combinations with other immunomodulatory agents, chemotherapy backbones and possibly newer targeted drugs, aiming to broaden or refine its use in B-cell malignancies.

For investors, one key watchpoint is whether these studies can generate data strong enough to support label expansions or move tafasitamab earlier in treatment lines, which could expand patient numbers and revenue. At the same time, competition from other agents in DLBCL and related diseases continues to intensify.

Context for MorphoSys AG stock

As MorphoSys’s first fully commercialized oncology antibody, Monjuvi plays an outsized role in how analysts view the company’s transition from a licensing-driven model to one based on product sales. Company presentations regularly break out Monjuvi/Minjuvi net product revenue, alongside royalty income from other partnered assets.

On Xetra, MorphoSys AG stock trades in euros under ISIN DE0006632003, and Monjuvi’s performance in the DLBCL market is one of several factors that investors track when assessing the company’s medium-term prospects, together with pipeline progress and broader oncology competition.